THERE IS THIS EASE, THIS SIMPLICITY, THIS INSPIRATION, WHEN WE WRITE ABOUT REVOLUTIONS. “Chimeric antigen receptor (CAR) T cell therapies are here to change the world,” we say (and have been saying for over a decade – in grants, in lay articles, in interviews). The cancer-stricken can now be cancer-free. Every disease can potentially be targeted: HIV, autoimmune disease, many others. But the impact of revolutions is only as good as the governing that happens after – the boring, tedious, trial-and-error part of making the dream available to all. Read More

For first-time – and even repeat – attendees to an ISCT Annual Meeting, the entire process of preparing for the conference, navigating the meeting, and actually making meaningful connections with other attendees can be daunting. To help alleviate these fears and offer helpful guidance, for this month’s Member Spotlight, the Telegraft Editorial Board’s own Ashley Krull, Ph.D., facilitated a conversation between experienced and novice conference attendees from the Cellular Therapy Laboratory at The Ohio State University James Cancer Hospital in Columbus, Ohio. Read More